Clinical Trial: Regulatory B Cells in Inflammatory Rheumatisms and Biomarkers of Response to Biologic Treatments

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Observational

Official Title: Regulatory B Cells in Inflammatory Rheumatisms, Systemic Auto-immune Diseases in Adults and Biomarkers of Response to Biologic Treatments

Brief Summary: B cells are known to play an important role in auto-immune diseases by activating T cells, secreting inflammatory cytokines and autoreactive antibodies. However, a sub-type of B cells named regulatory B cells or Bregs has recently shown capacities to prevent or cure arthritis in mouse models. Bregs have also been identified in humans.

Detailed Summary: B cells are known to play an important role in auto-immune diseases by activating T cells, secreting inflammatory cytokines and autoreactive antibodies. However, a sub-type of B cells named regulatory B cells or Bregs has recently shown capacities to prevent or cure arthritis in mouse models. Bregs have also been identified in humans. Main objective: To study Bregs abnormalities in patients with rheumatoid arthritis (RA) at different stages of the disease compared to subjects with mechanical pathologies.Secondary objectives:- To evaluate the specificity of any abnormalities identified in RA by studying Bregs in patients with other autoimmune or other inflammatory joint diseases.- To evaluate the effect of biological and synthetic treatments on Bregs in patients with RA. - To assess whether the rate of Bregs before treatment is predictive of response to biological and synthetic treatments.
Sponsor: University Hospital, Montpellier

Current Primary Outcome: Assessment of Bregs levels [ Time Frame: 30 months ]

The levels of Bregs will be assessed in patients with RA and compared to subjects with mechanical pathologies.


Original Primary Outcome: Same as current

Current Secondary Outcome: Change of Bregs levels after therapy [ Time Frame: 30 months ]

The levels of Bregs will be assessed in patients who will start a therapy within the framework of their usual follow-up.


Original Secondary Outcome: Same as current

Information By: University Hospital, Montpellier

Dates:
Date Received: July 11, 2012
Date Started: July 2012
Date Completion: July 2016
Last Updated: November 19, 2015
Last Verified: November 2015